Second pass at: Retatrutide mass and identity: what a report should show posts 61–72

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

This follows post #59 rather than contradicting it.

What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.

This settles it for me, at least until somebody posts a reason it should not.

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

The part I am sure of is shorter than the part I have written.

Post #64 and I disagree about the size of the effect, not about the direction.

Taking Retatrutide mass and identity seriously for a moment rather than deflecting: the honest position is that the community has observations and no controlled comparison, and those two things support very different sentences.

Taking post #64 at face value and following it one step further.

Marking my uncertainty on Retatrutide mass and identity explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.

No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.

The number is defensible. The precision I gave it is not.

Post #67 put the caveat in the right place and I want to underline it.

Nobody has said the unglamorous part of Retatrutide mass and identity yet, so: most of the variation is explained by things that are boring to write about and easy to check.

Reading back through the Retatrutide mass and identity threads from last year, the same three questions come up every time and only one of them has ever been answered properly. That seems like a documentation gap rather than a knowledge gap.

Post #70 answers the question as asked. The question underneath it is different.

Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.

I read post #69 twice before replying, because I had assumed the opposite.

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.